Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health supplement may calm inflammation in kidney dialysis patients

NCT ID NCT07694791

Disease control Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests whether a daily capsule containing probiotics and prebiotics can lower inflammation and improve nutrition in adults with chronic kidney disease who are on peritoneal dialysis. Participants take either the synbiotic or a placebo for six months, with blood tests and checkups at the start, three months, and six months. The study measures changes in inflammation markers, gut-derived toxins, and infection rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Synbiotic (probiotics plus prebiotic fibers)
What this could lead to
If it works, this could point toward a simple, low-cost way to reduce inflammation and infection risk in people on peritoneal dialysis.
What could go wrong
This is a small, early-stage trial with only 60 participants. The supplement may not significantly lower inflammation or prevent infections, and individual results may vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older. * Patients diagnosed with kidney disease who have been receiving peritoneal dialysis at home for at least 1 month. Exclusion Criteria: * Patients who are unable to eat or receive food through a feeding tube. * Patients who have taken prebiotics or probiotics (supplements that support gut health) in the month before the study starts. * Patients who used antibiotics in the month before the study starts. * Patients who cannot attend the scheduled follow-up visits (missing the second follow-up appointment will result in being removed from the study). * Note on non-adherence and withdrawal: Patients who are unable to take their assigned capsules regularly (taking less than 80% of the total capsules will result in being removed from the study).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease (stages 4 and 5) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease (stages 4 and 5) Peritoneal dialysis (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario Dr. José E. González, Centro Regional de Enfermedades Renales (CRER)

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.